Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Seminars in Dialysis, 2007; 20(3):191-194||en|
|dc.description||The definitive version is available at www.blackwell-synergy.com||en|
|dc.description.abstract||The linkage between bone parameters (calcium, phosphate, parathyroid hormone) and cardiovascular death in dialysis patients has led to a major resurgence in interest in this area of nephrological practice. Two major groups have recently published extensive guidelines for clinical practice in this area—the National Kidney Foundation's Kidney Disease Outcomes and Quality Initiative from the United States, and the Caring for Australasians with Renal Impairment group from Australia and New Zealand. There are some important differences in their recommendations, which reflect variations in local clinical practice, reimbursement systems, and interpretation of the medical literature. Two areas of divergence are highlighted in this editorial—use of vitamin D and its analogs, and use of phosphate binders. Readers of guidelines such as these need to be careful to interpret such recommendations in the context of the realities of their local clinical practice and availability of therapies.||en|
|dc.publisher||Blackwell Publishing Inc||en|
|dc.subject||Humans; Bone Diseases, Metabolic; Kidney Diseases; Calcinosis; Hyperparathyroidism; Calcitriol; Ergocalciferols; Chelating Agents; Renal Dialysis; Administration, Oral; Infusions, Intravenous; Internationality; Bone Density Conservation Agents; Practice Guidelines as Topic||en|
|dc.title||Managing bone parameters in dialysis patients: International guideline conflicts||en|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.